CHANGES IN THE FIBRINOLYTIC ACTIVITY OF BLOOD IN PATIENTS WITH CORONARY HEART DISEASE WITH CONCOMITANT DIABETES MELLITUS TYPE 2, DEPENDING ON THE COMPENSATION
DOI:
https://doi.org/10.11603/2415-8798.2018.4.9803Keywords:
thrombosis, hemostasis, ischemic heart disease, fibrinolytic system, type 2 diabetes mellitusAbstract
Disturbances in the hemostasis system have a serious effect on the course of the disease and the presence of complications in patients with comorbid flow of CHD and CD 2nd type.
The aim of the study – to evaluate and analyze the parameters of fibrinolysis in different groups of patients with coronary heart disease without and with associated diabetes mellitus (DM) type 2 depending on later.
Materials and Methods. During the study of the fibrinolytic system, 52 patients were hospitalized in the cardiology and endocrinology department of the Kyiv Clinical Hospital on the Railway Transport No. 2 with clinical signs of coronary artery disease. Patients were divided into three groups: 27 patients with IHD and with type 2 diabetes in the subcompensation stage, 14th – compensation stage and 11th – decompensation stage.
Results and Discussion. After analyzing the data, we found a decreased level of plasminogen in subcompensation by 15.5 % (p <0.001), with a compensation of 13 % (p <0.001), with decompensation by 17.2 % (p <0.05), as well as a significant increase in the activity of the Hageman-dependent fibrinolysis parameters (2.09 (p <0.001), 2.2 (p <0.001), 2.3 times (p <0.001) respectively) and the plasminogen-1 activator inhibitor (20 % (p <0.001), 19.8 % (p <0.001), 26 % (p <0.001). As a result, the revealed changes in the parameters of fibrinolysis, we observed a significant partial lengthening of euglobulin lysis: by 49.8 % (p < 0.001) with subcompensation, by 55.4 % (p <0.001) at compensation, on 55.7 % (p <0.001) at decompensation.
Conclusions. In patients with comorbidity of CHD and type 2 diabetes at different stages of compensation, we observed a suppression of the activity of the fibrinolytic potential of the blood. But in patients with type 2 diabetes at the stage of decompensation, it is most pronounced, which may be the reason for the more frequent development of micro-and macrosomal complications in this group of patients.
References
Ivashkina V.T. (Ed.) (2002). Bolezni pecheni i zholchevyvodiashchikh putei [Diseases of the liver and biliary tract]. Moskva, p. 432 [in Russian].
Horodetskiy, B.M. (1998). Oslozhneniya protivoopukholevoy terapii [Complications of antitumor therapy]. Gematologiia i transfusiologiia – Hematology and transfusiology, 1, 11-15 [in Russian].
Kan, V.K. (1997). Kholestaz: novoe v patogeneze, diagnostike i lechenii [Cholestasis: new in pathogenesis, diagnosis and treatment]. Rossiyskiy zhurnal gastroenterologii, gepatologii – Russian Journal of Gastroenterology, Hepatology, 3, 25-29 [in Russian].
Volkova, M.A. (Ed.) (2011). Klinicheskaya onkogematologiya [Clinical oncohematology]. Moskov: Meditsina, p. 572 [in Russian].
Maier, K.P. (2004). Gepatit i posledstviya gepatita: prakticheskoe rukovodstvo [Hepatitis and the consequences of hepatitis: a practical guide]. Moskov, p. 720 [in Russian].
Exadaktylos, P., Reiss, T., Schobess, R., Hommann, M., Höhne, S., & Beck, A. (1994). Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and non-Hodgkins lymphoma. Klin. Padiatr., 206 (4). 315-318.
Fowler, R., & Imrie, K. (2001). Thalidomide-associated hepatitis: a case report. Am. J. Hematol., 66 (4), 300-302.
Frezza, M., & Terpin, M. (1992). The use of S-adenosyl-L-methiorline in the treatment of cholestatic disorders. A meta-analysis of clinical trials. Drug Invest., 4 (Suppl. 4), 101-108.
Hoebe, K.H., Witkamp, R.F., Fink-Gremmels J., Van Miert, A.S., & Monshouwer, M. (2001). Direct cell-to-cell contact between Kupfer cells and hepatocytes augments endotoxin-induced hepatic injury. Am. J. Physiol. Gastrointest. Liver Physiol., 280 (4), G720-728.
Jansen, P.L., & Van der Lelie, H. (1994). Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin’s disease. Neth. J. Med., 44 (3), 99-102.
Vina, J. (Ed.) (1990). Glutathione Metabolism and Phisiological Functions Boston, p. 378.
Levis, J.H., & Schiff, E. (1998). Methotrexat-induced chronic liver injury: guidelines for detection and prevention. Am. J. Gastroenterol., 83, 1337.
Laidlaw, S.T., Reilly, J.T., & Suarna, S.K. (1995). Fatal hepatotoxicity associated with 6-mercaptopurine therapy. Postgrad Med. J., 71 (849), 639.
Santini, D., Vincenzi, B., Picardi, A., Gentilucci, U.V., Esposito, V., … & Tonini, G. (2003). S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res., 23 (6D), 5173-5179.
Wang, L., Gloves, J., Hepburn, M., & Bowen, D.T. (2000). Glutathione-S-transferase enzyme expression in hema¬topoietic cell lines implies a differential protective role for TI, and AI isoenzymes in erythroid and for MI in lymphoid lineages. Haematologica, 85 (6), 573-579.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
